nach oben

Journal of Clinical Immunology

Erschienen in:

01.05.2010

sHLA-I Contamination, A Novel Mechanism to Explain Ex Vivo/In Vitro Modulation of IL-10 Synthesis and Release in CD8⁺ T Lymphocytes and in Neutrophils Following Intravenous Immunoglobulin Infusion

verfasst von: Massimo Ghio, Paola Contini, Maurizio Setti, Gianluca Ubezio, Clemente Mazzei, Gino Tripodi

Erschienen in: Journal of Clinical Immunology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Numerous mechanisms have been proposed to explain the beneficial action of intravenous immune globulin (IVIG) in autoimmune and systemic inflammatory disorders; among others, they could decrease pro-inflammatory cytokine levels and also induce anti-inflammatory cytokines.

Materials and Methods

Ex vivo analysis of cells from ten IVIG recipients showed significant increase of IL-10 mRNA and intra-cellular IL-10 molecules in both leukotypes.

Results

In vitro comparable results were obtained incubating CD8⁺ T lymphocytes and neutrophils from healthy donors with IVIG. sHLA-I and/or sFasL immunodepletion abolished IL-10 modulation. Co-culture with contaminant-free IgM or MabThera did not exert any mRNA modulation. Finally, IgM or MabThera plus purified sHLA-I molecules enhanced IL-10-mRNA in both leukotypes to levels comparable to those obtained with IVIG incubation.

Conclusion

As IVIG infusion involves administration of soluble contaminants, these data consent to speculate that IVIG might modulate IL-10 via the immunomodulatory activities of sHLA-I contaminant molecules inducing transcriptional and post-transcriptional modulation of IL-10 in CD8⁺ T lymphocytes and neutrophils.

Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. NEJM. 2008;359:307–9.CrossRefPubMed

Seite J-F, Shoenfelf Y, Youinou P, Hillion S. What is the contents of magic draft IVIg? Autoimmun Rev. 2008;7:435–9.CrossRefPubMed

Sewell WAC, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology. 2002;107:387–93.CrossRefPubMed

Eibl MM. Intravenous immunoglobulins in neurological disorders: safety issues. Neurol Sci. 2003;24:S222–6.CrossRefPubMed

Bayry J, Thirion M, Misra N, Thorenoor N, Delignat S, Lacroix-Desmazes S, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci. 2003;24:S217–21.CrossRefPubMed

Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory Diseases with intravenous immune globulin. NEJM. 2001;345:747–55.CrossRefPubMed

Mouzaki A, Theodoropoulos M, Gianakopoulos I, Vlaha V, Kyrtsonosis M-C, Maniatis A. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenia purpura (ITP) at presentation and their modulation by intravenous immunoglobulin (IVIg) treatment: thei role in prognosis. Blood. 2002;100:1774–9.PubMed

Bayry J, Kazatchkine MD, Kaveri SV. Shortage of human intravenous immunoglobulin, reasons and possible solutions. Nat Clin Pract Neurol. 2007;3(3):120–1.CrossRefPubMed

Skansén-Saphir U, Andersson J, Björk L, Ekberg C, Fehniger TE, Henter JI, et al. Down-regulation of lymphokine synthesis by intravenous gammaglobulin is dependent upon accessory cells. Scand J Immunol. 1998;47(3):229–35.CrossRefPubMed

10.

Amran D, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol. 1994;73(2):180–6.CrossRefPubMed

11.

Modiano JF, Amran D, Lack G, Bradley K, Ball C, Domenico J, et al. Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobulin. Clin Immunol Immunopathol. 1997;83(1):77–85.CrossRefPubMed

12.

Toyoda M, Zhang XM, Petrosian A, Wachs K, Moudgil A, Jordan SC. Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma-globulin. Transpl Immunol. 1994;2(4):337–41.CrossRefPubMed

13.

Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet. 1993;341:789–90.CrossRefPubMed

14.

Grosse-Wilde H, Blasczyk R, Westhoff U. Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tissue Antigens. 1992;39:74–7.CrossRefPubMed

15.

Ghio M, Contini P, Puppo F, Indiveri F. The immunomodulatory effect of blood transfusions and intravenous immunoglobulins: the role of the soluble molecules of the Class-I major histocompatibility complex and of the Fas ligand. Ann Ital Med Int. 2000;15(1):70–4.PubMed

16.

Ghio M, Ottonello L, Contini P, Amelotti M, Mazzei C, Indiveri F, et al. Transforming growth factor-beta1 in supernatants from stored red blood cells inhibits neutrophil locomotion. Blood. 2003;102:1100–7.CrossRefPubMed

17.

Ghio M, Contini P, Mazzei C, Brenci S, Barberis G, Filaci G, et al. Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood. 1999;3:1770–7.

18.

Ghio M, Contini P, Ubezio G, Mazzei C, Puppo F, Indiveri F. Immunomodulatory effects of blood transfusions: the synergic role of soluble HLA Class I free heavy-chain molecules detectable in blood components. Transfusion. 2008;48:1591–7.CrossRefPubMed

19.

Ghio M, Contini P, Mazzei C, Merlo A, Filaci G, Setti M, et al. In vitro immunosuppressive activity of soluble HLA class I and Fas ligand molecules: do they play a role in autologous blood transfusion? Transfusion. 2001;41:988–96.CrossRefPubMed

20.

Ghio M, Contini P, Negrini S, Proietti M, Gonella R, Ubezio G, Ottonello L, Indiveri F. sHLA-I contaminating molecules as novel mechanism of ex vivo/in vitro transcriptional and post transcriptional modulation of TGFβ₁ in CD8⁺ T lymphocytes and neutrophils following intravenous immunoglobulin treatment. Transfusion. 2009 (in press)

21.

Tanabe M, Sekimata M, Ferrone S, Takiguchi M. Structural and functional analysis of monomorphic determinants recognized by monoclonal antibodies reacting with the HLA class I alpha 3 domain. J Immunol. 1992;148:3202–9.PubMed

22.

Pellegrino MA, AK NG, Russo C, Ferrone S. Heterogeneous distribution of the determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules. Transplantation. 1982;34:18–23.CrossRefPubMed

23.

Nakajima H, Samaridis J, Angman L, Colonna M. Human myeloid cells express an activating ILT receptor (ILT1) that associates with Fc receptor gamma-chain. J Immunol. 1999;162(1):5–8.PubMed

24.

Ottonello L, Ghio M, Contini P, Bertolotto M, Bianchi G, Montecucco F, et al. Nonleukoreduced red blood cell transfusion induces a sustained inhibition of neutrophil chemotaxis by stimulating in vivo production of transforming growth factor-beta1 by neutrophils: role of the immunoglobulinlike transcript 1, sFasL, and sHLA-I. Transfusion. 2007;47:1395–404.CrossRefPubMed

25.

Contini P, Ghio M, Merlo A, Poggi A, Indiveri F, Puppo F. Apoptosis of antigen-specific T lymphocytes upon the engagement of CD8 by soluble HLA class I molecules is Fas ligand/Fas mediated: evidence for the involvement of p56lck, calcium calmodulin kinase II, and Calcium-independent protein kinase C signaling pathways and for NF-kappaB and NF-AT nuclear translocation. J Immunol. 2005;175:7244–54.PubMed

26.

Puppo F, Contini P, Ghio M, Brenci S, Scudeletti M, Filaci G, et al. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. Int Immunol. 2000;12:195–203.CrossRefPubMed

27.

Vassilev T, Mihaylova N, Voynova E, Nikolova M, Kazatchkine M, Kaveri S. IgM-enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu-SCID mice. Clin Exp Immunol. 2006;145:108–15.CrossRefPubMed

28.

Prasad NKA, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, et al. Therapeutic preparation of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving Fas apoptotic pathway. J Immunol. 1998;161:3781–90.PubMed

29.

Kivity S, Katz U, Daniel N, Nussinovitch U, Papageorgiou N, Shoenfeld Y. Evidence for the use of intravenous immunoglobulins—a review of the literature. Clin Rev Allergy Immunol. 10 Jul 2009 (in press)

30.

Seite JF, Shoenfeld Y, Youinou P, Hillion S. What is the contents of the magic draft IVIg? Autoimmun Rev. 2008;7(6):435–9.CrossRefPubMed

31.

Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat Clin Pract Rheumatol. 2007;3(5):262–72.CrossRefPubMed

32.

Zandman-Goddard G, Blank M, Shoenfeld Y. Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside. Lupus. 2009;18(10):884–8.CrossRefPubMed

33.

Gold R, Stangel M, Dalakas MC. Drug Insight: the use of intravenous immunoglobulin in neurology–therapeutic considerations and practical issues. Nat Clin Pract Neurol. 2007;3(1):36–44.CrossRefPubMed

34.

Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008;26:513–33.CrossRefPubMed

35.

Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol. 2008;29(12):608–15.CrossRefPubMed

36.

Le Pottier L, Sapir T, Bendaoud B, Youinou P, Shoenfeld Y, Pers JO. Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann N Y Acad Sci. 2007;1110:426–32.CrossRefPubMed

37.

Spaggiari GM, Contini P, Dondero A, Carosio R, Puppo F, Indiveri F, et al. Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. Blood. 2002;100:4098–107.CrossRefPubMed

38.

Li MO, Flavell RA. TGF-beta: a master of all T cell trades. Cell. 2008;134:392–404.CrossRefPubMed

39.

Wahl SM. Transforming growth factor-beta: innately bipolar. Curr Opin Immunol. 2007;19:55–62.CrossRefPubMed

40.

Lories RJ, Casteels-Van Daele M, Ceuppens JL, Van Gool SW. Polyclonal immunoglobulins for intravenous use induce interleukin 10 release in vivo and in vitro. Ann Rheum Dis. 2004;63(6):747–8.CrossRefPubMed

41.

Ghio M, Contini P, Negrini S, Boero S, Musso A, Poggi A. Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity. Eur J Immunol. 2009;39(12):3459–68.CrossRefPubMed

42.

Spolski R, Kim HP, Zhu W, Levy DE, Leonard WJ. IL-21 mediates suppressive effects via its induction of IL-10. J Immunol. 2009;182(5):2859–67.CrossRefPubMed

43.

Ince MN, Elliott DE, Setiawan T, Metwali A, Blum A, Chen HL, et al. Role of T cell TGF-beta signaling in intestinal cytokine responses and helminthic immune modulation. Eur J Immunol. 2009;39(7):1870–8.CrossRefPubMed

44.

Yang BC, Lin HK, Hor WS, Hwang JY, Lin YP, Liu MY, et al. Mediation of enhanced transcription of the IL-10 gene in T cells, upon contact with human glioma cells, by Fas signaling through a protein kinase A-independent pathway. J Immunol. 2003;171(8):3947–54.PubMed

45.

Fainardi E, Rizzo R, Castellazzi M, Stignani M, Granieri E, Baricordi OR. Potential role of soluble human leukocyte antigen-G molecules in multiple sclerosis. Hum Immunol. 2009;70(12):981–7.CrossRefPubMed

46.

Mapp CE, Ferrazzoni S, Rizzo R, Miotto D, Stignani M, Boschetto P, et al. Soluble human leukocyte antigen-G and interleukin-10 levels in isocyanate-induced asthma. Clin Exp Allergy. 2009;39(6):812–9.CrossRefPubMed

Titel: sHLA-I Contamination, A Novel Mechanism to Explain Ex Vivo/In Vitro Modulation of IL-10 Synthesis and Release in CD8+ T Lymphocytes and in Neutrophils Following Intravenous Immunoglobulin Infusion
verfasst von: Massimo Ghio
Paola Contini
Maurizio Setti
Gianluca Ubezio
Clemente Mazzei
Gino Tripodi
Publikationsdatum: 01.05.2010
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 3/2010
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-009-9364-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

sHLA-I Contamination, A Novel Mechanism to Explain Ex Vivo/In Vitro Modulation of IL-10 Synthesis and Release in CD8⁺ T Lymphocytes and in Neutrophils Following Intravenous Immunoglobulin Infusion

Abstract

Background

Materials and Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Background

Materials and Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Immunoglobulin G from Breast Cancer Patients in Stage I Stimulates Muscarinic Acetylcholine Receptors in MCF7 Cells and Induces Proliferation. Participation of Nitric Oxide Synthase-Derived Nitric Oxide

Differential Suppression of Heat-Killed Lactobacilli Isolated from kimchi, a Korean Traditional Food, on Airway Hyper-responsiveness in Mice

Toll-like Receptor Expression on Peripheral Blood Mononuclear Cells in Asthmatics; Implications for Asthma Management

Proteolytically Inactive Per a 10 Allergen of Periplaneta americana Modulates Th2 Response and Enhances IL-10 in Mouse Model

Impaired Antigen Processing and Presentation Machinery is Associated with Immunotolerant State in Chronic Hepatitis B Virus Infection

Influenza-Induced Production of Interferon-Alpha is Defective in Geriatric Individuals

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin